Miguel Romanello Giroud Joaquim1, Emma E Furth2, Yong Fan2, Hee Kwon Song2, Stephen Pickup2, Jianbo Cao3, Hoon Choi2, Mamta Gupta2, Cynthia Clendenin2, Thomas Karasic2, Jeffrey Duda2, James Gee2, Peter O'Dwyer2, Mark Rosen2, and Rong Zhou1
1Department of Radiology, University of Pennsylvania, Philadelphia, PA, United States, 2University of Pennsylvania, Philadelphia, PA, United States, 3University of Cambridge, Cambridge, United Kingdom
Synopsis
Intraductal Papillary Mucinous Neoplasms (IPMN) are recognized as important precursors
to invasive pancreatic ductal adenocarcinoma (PDAC). While IPMN requires
surveillance without treatment, a clinical marker is lacking which can identify
those undergoing malignant transformation. In two genetic engineered mouse
models (KPC and CKS), which resemble human PDAC and IPMN, respectively, we
tested the hypothesis that differences in cellular architecture and stromal
features between PDAC and IPMN present themselves in DW-MRI and /or DCE-MRI
metrics. Our data revealed an almost complete separation of ADC values between
CKS (benign) vs. KPC (malignant) tumors and identified histopathological
features corroborating the imaging metrics.
Introduction
Human pancreatic ductal adenocarcinoma (PDAC) has prevailing
genetic signatures including KRAS, TP53mutation and/or SMAD4 deletion. Hence, genetic
engineered mouse (GEM) models provide powerful tools to study malignant
transformation. Mice with
simultaneous mutations of KRAS and TP53 in pancreas epithelium (KrasG12D:Trp53R172H:Pdx1-Cre,
referred to as KPC) develop tumors resembling human PDAC with high penetrance and reproducible kinetics[1, 2]. In
contrast, mice carrying KRASG12Dand SMAD4 deletion (KrasG12D:Smad4L/L:Ptf1a-Cre,
CKS) harbor tumors that resemble human intraductal papillary mucinous neoplasms
(IPMN) [3]. IPMN is
considered premalignant thus surgical excision is not recommended until progression
to malignant PDAC is suspected. However, there is no clinical biomarker that
can guide management of IPMN patients. DW-MRI and DCE-MRI are two clinic
translated quantitative imaging methods sensitive to tumor cellularity
and the stromal microenvironment. We hypothesize that differences in cellular
architecture and stromal features between PDAC and IPMN can be revealed by
DW-MRI and/or DCE-MRI metrics. We test this hypothesis by comparing MRI metrics
for KPC versus CKS models alongside detailed histopathological analyses. Methods
A total of 44 KPC and 20 CKS mice were studied
in DW-MRI,
of which 21 and 11 respectively were studied in DCE-MRI. A group of 11 KPC mice with similar tumor
volumes was for comparison with the CKS group. 5 KPC and 7 CKS mice were
studied in histopathology, with small overlap with MRI mice. In vivo MRI was performed on a 9.4T Avance III (Bruker, Berillica, MA) equipped with a 12-cm, 40
gauss/cm gradient coil with a maximum slew rate of 11.5 T/cm sec. Animal
preparation and vital signs monitoring during MRI were described by us elsewhere
[4-6]. Radial
k-space sampling diffusion-weighted spin echo protocol (Rad-SE-DW),
reconstruction and analyses were developed recently [6] and optimized here (e.g.,
respiration gating was deemed unnecessary). Golden-angle radial 3D acquisition
(stack-of-star, SOS) was initially developed by HKS
(coauthor) on clinical MRI [7], has been
reverse engineered to animal 9.4T spectrometer and applied to B1
and T1 mapping and DCE series during DCE-MRI (detailed
in the abstract by Pickup). From DW-MRI: apparent diffusion coefficient (ADC)
and kurtosis index (KI) were obtained.
From DCE-MRI: tumor T1, Ktrans, and Ve indices were obtained using
a reference region model [8, 9].
All immunohistopathological studies were performed on
FFPE tissue sections stained for H&E, Sirius Red (collagen) or CD31
(microvasculature). Stained sections were digitized using AperioScanScope(Leica)
and analyzed in QuPath[10]. Two-tailed tests were conducted to compare metrics
between the two models. Results
On T2W MRI, KPC tumor presents as a single, solid tumor,
consistent with gross dissection (Fig 1A). In contrast, CKS tumor
presents as a lobulated mass with small cysts featuring high signals (Fig 1B).
DW images of both GEM models are free of respiratory motion artifacts even at
the highest b value, leading to good quality ADC and KI maps (Fig 2A-B).
ADC values of CKS tumors are significantly higher than KPC tumors with almost
no overlap (Fig 2C), while KI (non-gaussian diffusion) values are
significantly lower in CKS model (Fig 2D) – MRI metrics are summarized
in Table-1.
We identified several cellular architecture and histological features which may underlie
the distinct DWI metrics between the two GEM models (Table-2). H&E
stains suggest that the KPC model has an abrupt invasive adenocarcinoma tumor
formation without intra-ductal growth (Fig 3A-B with magnified region in Fig
3C-D). In contrast, CKS tumors are initiated from multifocal epithelial
proliferation within ducts; the growth pattern shows folding and papillary
architecture resembling the human IPMN; the multi-focal CKS tumors are relatively
small with residual, mucin-containing pancreatic acinar parenchyma
(Fig 2E-F with magnified region in Fig 2G-H). The KPC adenocarcinoma
formation is much smaller than the intra-ductal gland architecture in the CKS
model (Fig 3C-D vs. Fig 3E-F). Features corroborating high ADC and low KI in
CKS tumors include: 1. Intraductal cystic growth; 2. Less dense tumor bed as
the result of multiple colonies as opposed to abrupt tumor formation from a
single colony for KPC. Cell density was shown to be significantly higher in the
KPC specimens when entire sections were compared (Table-2).
The SOS protocol results in DCE series without respiratory
motion blurring. Fig 3A and B reveal high resolution Ktrans
maps of a KPC and CKS tumor respectively. A poorly perfused center
surrounded by a well-perfused rim is typical for KPC tumors, which is
consistent with CD31 staining distribution (data not shown), whereas Ktrans
of CKS tumors is more uniform. Group-wise, CKS tumors higher Ve (p = 0.09) and significantly lower T1 values
than KPC model (Table-1). Compared to CKS, KPC exhibits a trend of significantly
lower Ktrans values accompanied by a significantly higher microvascular
density (Table-2). Discussion
Quantitative DCE- and DW-MRI combined with
detailed immunohistochemistry elucidate histopathological bases of imaging
metrics. The paradoxical finding between high microvascular density vs. low Ktrans values in KPC
might be explained by its high
interstitial fluid pressure [11], which would reduce or shutdown vascular perfusion and/or permeability
in KPC tumors. Conclusion
CKS model resembles
key features of human IPMN. Cystic growth of CKS underlies their distinctly
higher ADC values, thereby not overlapping with the KPC tumor’s ADCs, and therefore,
this metric might be used to distinguish IPMN from malignant PDAC. Acknowledgements
Funding support from NIH : U24-CA-231858References
[1] S.R. Hingorani, L.
Wang, A.S. Multani, C. Combs, T.B. Deramaudt, R.H. Hruban, A.K. Rustgi, S.
Chang, D.A. Tuveson, Cancer Cell, 7 (2005) 469-483.
[2] S.R. Hingorani, E.F.
Petricoin, A. Maitra, V. Rajapakse, C. King, M.A. Jacobetz, S. Ross, T.P.
Conrads, T.D. Veenstra, B.A. Hitt, Y. Kawaguchi, D. Johann, L.A. Liotta, H.C.
Crawford, M.E. Putt, T. Jacks, C.V. Wright, R.H. Hruban, A.M. Lowy, D.A.
Tuveson, Cancer Cell, 4 (2003) 437-450.
[3] N. Bardeesy, K.H.
Cheng, J.H. Berger, G.C. Chu, J. Pahler, P. Olson, A.F. Hezel, J. Horner, G.Y.
Lauwers, D. Hanahan, R.A. DePinho, Genes & development, 20 (2006)
3130-3146.
[4] P. Bagga, S. Pickup,
R. Crescenzi, D. Martinez, A. Borthakur, K. D'Aquilla, A. Singh, G. Verma, J.A.
Detre, J. Greenberg, H. Hariharan, R. Reddy, Scientific reports, 8 (2018) 2883.
[5] J. Cao, S. Pickup,
C. Clendenin, B. Blouw, H. Choi, D. Kang, M. Rosen, P.J. O'Dwyer, R. Zhou, Clin
Cancer Res, 25 (2019) 2314-2322.
[6] J. Cao, H.K. Song,
H. Yang, V. Castillo, J. Chen, C. Clendenin, M. Rosen, R. Zhou, S. Pickup,
Tomography : a journal for imaging research, 7 (2021) 66-79.
[7] H.K. Song, L.
Dougherty, Magn Reson Med, 44 (2000) 825-832.
[8] T.E. Yankeelov, J.J.
Luci, M. Lepage, R. Li, L. Debusk, P.C. Lin, R.R. Price, J.C. Gore, Magnetic
Resonance Imaging, 23 (2005) 519-529.
[9] J.
Cárdenas-Rodríguez, C.M. Howison, M.D. Pagel, Magn Reson Imaging, 31 (2013)
497-507.
[10] P. Bankhead, M.B.
Loughrey, J.A. Fernández, Y. Dombrowski, D.G. McArt, P.D. Dunne, S. McQuaid,
R.T. Gray, L.J. Murray, H.G. Coleman, J.A. James, M. Salto-Tellez, P.W.
Hamilton, Scientific reports, 7 (2017) 16878.
[11] P.P. Provenzano, C. Cuevas, A.E. Chang, V.K.
Goel, D.D. Von Hoff, S.R. Hingorani, Cancer Cell, 21 (2012) 418-429.